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Diabetes is increasing in the world and causes severe cardiovascular complications. Diabetes-induced limb ischemia leads to foot amputation and therapeutic remedies are urgently needed. Here we report that local injection of mesenchymal stem cells (MSCs) prestimulated with epidermal growth factor (EGF) restored blood flow and vasculogenesis in the ischemic hind-limb of type II diabetic (db À /db À ) mice. Bone marrow cells from db À /db À mice are altered as evidenced by increased oxidative stress and reduced Akt and adhesion molecules when compared with control (db À /db þ ). Femoral artery ligation-induced ischemia was performed in the hind-limb of db À /db À and db À /db þ mice for 28 days. Enhanced green fluorescent protein (EGFP)-MSCs stimulated±exogenous EGF for 24 h were injected locally into the ischemic muscle. Blood flow measured with MoorLDI-Laser and microangiography assessed with X-ray showed 100% recovery in db À /db þ compared to 50% recovery in db À /db À mice. Interestingly, db À /db À mice had 60 and 96% blood flow recovery and 61 and 98% of vasculogenesis when treated with MSCs alone or MSCs modified with EGF, respectively. Western blot analysis of hind-limb muscles revealed an increase in Akt and vascular endothelial growth factor receptor phosphorylation and hypoxia-inducible factor) expression in db À /db À mice injected with MSCs or MSCs þ EGF compared to db À /db À mice. Fluorescent microscopic images show that EGFP-MSCs differentiate into new microvessels. Adhesion and migration of MSCs on cultured endothelial cells were ICAM1-, VCAM1-and Akt-dependent mechanism and elevated when MSCs were prestimulated with EGF compared with nonstimulated MSCs. Our novel study data provide evidence that in type II diabetes, stimulated MSCs with EGF enhance the recovery of blood flow and angiogenesis. 
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Diabetes mellitus is a serious risk factor leading to vascular complication and the development of atherosclerotic, endstage renal failure, blindness and heart disease. 1 In fact, cardiac morbidity and mortality in patients with diabetes mellitus are greatly enhanced, 2 and up to 80% in diabetic patients, associated with vascular disease. 3 Peripheral vascular disease (PVD) associated with impaired vasculogenesis is another major problem in diabetic patients. It affects 7.5% diabetic patients aged between 60 and 64 years in the USA, and PVD is responsible for 3900 lower limb amputation per million in a year. 4 Recently, a growing number of studies reported abnormalities of neovascularization in diabetic patients with coronary or peripheral artery diseases, 5 and abnormal enhanced angiogenesis. 6 In addition, defective arteriogenesis, another form of vessel growth refers to the transformation of preexisting arteriolar pathways into large conductance arteries, has also been reported in patients with diabetes mellitus. 7 The underlying mechanism of this neovascularization defects still remains unclear. Recent evidence indicates that endothelial progenitor cells isolated from diabetic patients show a marked defect in migration in response to vascular endothelial growth factor (VEGF). 8 Interestingly, it has been advanced that multipotent stromal cells (MSCs) can differentiate into cardiomyocytes, endothelial cells (ECs) and smooth muscle cells. 9 In addition, previous reports describe the beneficial effect of administration of MSCs into injury tissue and indicate that they exert a paracrine effect in the repair of tissue. 10 The initial steps following injection of MSCs are homing to impaired tissue, adhesion, diapedesis and migration. 11 All these events are critical in the beneficial effect of injected MSCs. Therefore, increasing the homing, adhesion and migration could significantly enhance the therapeutic effect of injected MSCs. Thus, in previous studies, growth factors were used to improve the therapeutic effect of MSCs. 12 Interestingly, recent studies showed the importance of epidermal growth factor (EGF) or the EGF family member, HB-EGF (heparin-binding epidermal growth factor-like growth factor), in the differentiation of humanderived MSCs into ECs, adhesion of fibroblast 13 and angiogenesis.
14 Thus, we hypothesize that MSCs prestimulated with EGF can significantly facilitate the recovery of neovasculogenesis and subsequently improve tissue perfusion. The purpose of this study was to determine the potential therapeutic effect of locally injected stem cells alone or treated with EGF on vasculogenesis in the ischemic hindlimb of type II diabetic mouse (db
MATERIALS AND METHODS Antibodies
Phosphorylated VEGF receptor (Tyr845), VEGF, total Akt, phosphorylated Akt (Ser476), phosphorylated p40Phox (Thr154), Von Willebrand factor, total eNOS, hypoxia inducible factor (HIF), ICAM1 and VCAM1 were purchased from Cell Signaling and Promega. Drugs PI3-kinase inhibitor (LY-294002, 1 mM) and EGF were purchased from Sigma.
Bone Marrow Isolation
Bone marrow was isolated from db À /db À and their control as previously reported. 15 Mice Multipotent Stromal Cells Mice multipotent stromal cells were provided by the Gene Therapy Center, Tulane University. MSCs were collected from the bone marrow of the femurs and tibias of 8-to 10-weekold C57/Bl6 mice. mMSCs were obtained from the inbred transgenic strain C57Bl/6-TgN(ACTbEGFP)1Osb (GFPtg) that expressed enhanced green fluorescent protein (EGFP; Jackson Laboratories) for identification as previously described. 16 The isolation and purification of MSCs was described in detail by Dobson et À /db À mice were subjected to local injection, MSCs (200 000 per injection) stimulated±10 ng/ml of exogenous EGF for 24 h, in the three muscles (quadriceps 'U', gluteus 'L' and tibia 'T') of the right hind-limb just after femoral artery ligation. Then, mice received MSCs once a week for 3 weeks. As control, a group of db À /db À mice were subjected to local injection of PBS only.
Laser Doppler Measurement of Hind-Limb Blood Flow
Hind-limb blood flow measurement over the region of interest was performed at baseline before surgery, immediately postoperatively and serially over the 4-week period with laser Doppler perfusion imaging (Moor Instruments).
X-Ray Quantification of Hind-Limb Angiogenesis
Vessel density was assessed by high-definition microangiography at the end of the treatment period, as previously described. 18 Western Blot Analysis Western blot analysis of tissue and cultured cells was performed as previously described. [19] [20] [21] The quantification of western blot was determined using Multi Gauge software (Fujifilm).
Immunohistochemistry
Immunohistochemistry was performed as previously described. 19, 21, 22 MSCs are tagged with EGFP and do not have to be labeled for easy visualization.
Cultured Endothelial Cells from Microvessels
Endothelial cell isolation and culture were performed as previously described. 19 Briefly, 6-8 hearts from C57/Bl6 were isolated and perfused with Hanks' balanced salt solution supplemented with 175 U/ml of collagenase II (Worthington) and 0.25 mg/ml of elastase for 45 min. The collected ECs were then placed in a flask coated with fibronectin. ECs at passages 3-8 were used for adhesion, migration assay and western blot analysis.
Adhesion Assay of MSC Endothelial cells were cultured to confluency and then serum starved for 48 h. EGFP-MSCs ± exogenous EGF were placed on confluent ECs for 15 min, 2, 3, 4 and 24 h. Using another experimental design, we pretreated EGFP-MSCs with ICAM1 and/or VCAM1 antibodies and PI3-kinase inhibitor±EGF then placed on confluent cultured ECs for 24 h. At the end of experiment cells were washed, fixed and then adherent cells were counted under fluorescent microscope.
Migration Assay of MSC
Migration assay was performed using cell culture inserts (3 mm pore size; Millipore, MA, USA) coated with 2.5 mg/ml of fibronectin (BD Biosciences, Bedford, MA, USA). MSCs ± EGF were collected, counted and then applied (500 cells per well) on endothelial monolayer. Cells were incubated for 0, 2, 4 and 8 h time points for real-time recording migration assay at 371C and 5% CO 2. Transmigration was monitored by phase video microscopy (Olympus 1X81) at Â 20 magnification. Images were collected every 30 min for 8 h with a Hamamatsu C4880 charge-coupled device camera run by MetaMorph imaging software. For standard assay, we incubated cells for 24 h, then the upper surface of the filter was rapidly wiped with a cotton swab to remove nonmigratory cells and immediately the migrated cells were fixed in 10% formalin. EGFP-MSCs were counted under a phase-contrast microscope equipped with ocular grids.
Statistical Analysis
Results are expressed as mean ± s.e.m. One-way or two-way ANOVA was used to compare each parameter when there were two independent groups. Comparisons between groups were performed with Bonferroni post hoc t-tests when the ANOVA was statistically significant. Values of Po0.05 were considered statistically significant.
RESULTS

Bone Marrow Stem Cell Alterations in Type II Diabetes
We isolated bone marrow from db À /db À and db À /db þ mice and then subjected to western blot analysis for phosphorylated and total Akt, and p-40Phox. The data revealed that bone morrow cells from db À /db À mice express less phosphorylated and total Akt compared with control ( Figure 1a and b). In contrast, phosphorylated p-40Phox was significantly increased in bone morrow cells from db Figure 1c ). Figure 1d and e illustrates that adhesion molecules (ICAM1 and VCAM1) were significantly reduced in bone marrow cells from db
Effects of Local Injection of MSCs±EGF on Blood Flow
Recovery in Ischemic Hind-Limb in db À /db À Mice After femoral ligation, the blood flow was significantly reduced (less than 2% of the value before ligation) in all groups (Figure 2a Mice received intramuscular injection of MSCs (200 000 cells in 100 ml of sterile PBS) as a bolus into the upper, lower 
Effects of Local Injection of MSCs ± EGF on Vessel Density in Ischemic Hind-Limbs in db
À /db À Mice Vessel density was evaluated by high-definition microangiography at the end of the treatment period. We injected contrast media (barium sulfate, 0.5 g/ml) into the abdominal aorta. Angiography of the right and left hind-limbs was assessed and then a digital X-ray transducer acquired the images. After 4 weeks, vessel density was not different between the ischemic (right) leg and the nonischemic (left) legs in db Figure 3b ). By fluorescent microscopy, EGFPMSCs were visualized at low and high power of magnification. Data revealed that EGF-MSCs were able to differentiate to neovessels when injected to ischemic hind-limb of db À /db À mice (Figure 3a) . (Figure 4a and b) .
Effects of Local
Effects of Local Injection of MSCs ± EGF on eNOS and HIF Expression in Ischemic Hind-Limb in db À /db À Mice Figure 5a shows the effect of MSCs on total eNOS expression. In db 
Effect of EGF on MSCs Adhesion to Endothelial Cells
The adhesion of MSCs to ECs was time dependent (Figure 6a and b). The prestimulation of MSCs with EGF for 24 h before incubation with ECs significantly increased the adhesion rate of MSCs to ECs in a time-dependent manner ( Figure 6b ). The adhesion of MSCs to ECs was significantly decreased by the blockade of ICAM1 and VCAM1 (Figure 6c ). Similarly, specific antibodies of VCAM1 and ICAM1 significantly reduced the EGF MSC-induced adhesion to ECs (Figure 6b ). When both specific antibodies of ICAM1 and VCAM1 were added to MSCs untreated or prestimulated with EGF before incubation with ECs, the adhesion to ECs was significantly reduced compared with MSCs±EGF ( Figure 6c) ; however no additive effect was observed compared with ICAM-1 or 
VCAM-1 antibodies alone (Figure 6c). Pretreated MSCs with PI3-kinase inhibitor significantly reduced the adhesion of MSCs stimulated ± EGF to ECs (Figure 6c).
Effect of EGF and AKT on MSCs Migration
The migration of MSCs through ECs was time dependent (Figure 7a and b) . The stimulation of MSCs with EGF before incubation with ECs significantly increased their migration in a time-dependent manner (Figure 7a and b) . Moreover, the treatment of MSCs with PI3-kinase inhibitor (LY-294002, 1 mM) significantly decreased the migration through ECs of MSCs and MSCs stimulated with EGF (Figure 7c ). diabetes. 23, 24 The hind-limbs of type II diabetic mice were subjected to ischemia for 4 weeks. Our study data revealed that db À /db À mice show reduced blood flow recovery when compared with db À /db þ mice, indicating that angiogenesis was compromised in type II diabetes. These data are in agreement with previous studies showing that neovascularization is altered in type II diabetic patients and in an animal model. [25] [26] [27] Interestingly, the treatment of db À /db À mice with local injection of MSCs alone or MSCs stimulated with EGF show a significant enhancement in blood flow recovery reaching 100% with MSCs prestimulated with EGF. Our study data are in agreement with those of our previous study showing that MSCs prestimulated with EGF enhance collateral vessel growth in the rat heart after repetitive episodic serials of ischemia/reperfusion. 22, 28, 29 The increased efficiency of modified stem cells was also reported in a previous studies showing that lentivirally mediated gene transfer in transplanted stem cells increases in vivo chemoprotection of progenitor cells. 30 A number of reports show the angiogenic potential of EGF administration in ischemic tissue. We have previously shown that EGFR tyrosine kinase phosphorylation is increased in db À /db À mice as is associated with microvascular dysfunction. 19 In addition, it has been shown that increased HB-EGF, an agonist of EGFR tyrosine kinase, failed to induce angiogenesis in ischemic tissue. 31 On the basis of these observations, we did not treat db À /db À mice with exogenous EGF.
DISCUSSION
Using an alternative strategy, we evaluated the formation of new vessels in ischemic hind-limb of mice injected with contrast media to assess vascularization with X-ray. 22, 30 From these data, it is clear that the stimulation of MSCs with EGF before injection is in part to facilitate the integration of the MSCs and increase their availability in the ischemic tissue.
The mechanism of how MSCs improve vascularization and subsequently blood flow is unknown. It is more likely that MSCs exert paracrine effects 32 and/or differentiate into vascular cells. 33 In this study, we have shown that injected MSCs can differentiate into new vessels. These data are in agreement with previous studies showing the formation of new vessels from stem cells. 33 It is also more likely that paracrine effects and differentiation coexist and function together for a beneficial response of the MSCs. The mechanism dictating stem cells differentiation to vascular cells is still unknown. Nevertheless, studies by Madeddu and co-workers 34 showed that stem cells could release VEGF and interleukin-8, 35 and differentiate into vascular cells involved in the formation of new vessels. 33 In our study we focused on factors known to be involved in angiogenesis, such as HIF, VEGF, VEGF receptor phosphorylation, eNOS and Akt. 37 Interestingly, db À /db À mice injected with MSCs alone or MSCs stimulated with EGF significantly increased HIF and eNOS expression in the ischemic hind-limb of db À /db À mice. The effect of MSCs prestimulated with EGF was significant compared to the effect of MSCs alone. These data indicate that MSCs stimulated with EGF restore blood flow by increasing vessel formation more through the HIF, VEGF-VEGF receptor and eNOS pathways. Our study data are in agreement with previous studies showing an alteration in eNOS and the VEGF pathway in type II diabetes. 19, 36 It was also reported that treatment of ischemic tissue with stem cells (EP cells) restored eNOS expression and the VEGF pathway. 38 The first step of injected MSCs to tissue is adhesion, migration and engraftment. To determine the intracellular pathway involved in adhesion and migration, we performed adhesion and migration assays of MSCs on cultured ECs isolated from microvessels. We have shown that the adhesion of MSCs to confluent cultured ECs was time dependent. Interestingly, adhesion of MSCs was significantly higher when MSCs were prestimulated with EGF. To determine the mechanism involved in the adhesion of MSCs to ECs, we pretreated MSCs with PI3-kinase/Akt pathway inhibitor and specific antibodies for the adhesion molecules (ICAM1 and VCAM1). Our study data revealed that the PI3-kinase/Akt pathway and adhesion molecules (ICAM1 and VCAM1) were important in the adhesion of MSCs to ECs. To strengthen our point we performed western blots analysis on MSCs stimulated with EGF and the data illustrated that phosphorylated Akt is increased in a time-dependent manner. We have also shown that MSCs stimulated with EGF for 24 h significantly increase ICAM1 and VCAM1 expression in an Aktdependent-mechanism manner. Similarly, MSCs migration through ECs was time dependent and significantly enhanced when MSCs were stimulated with EGF. The inhibition of PI3-kinase/Akt pathway significantly reduced the migration of MSCs indicating the importance of the Akt pathway.
The use of stem cells for cellular therapy becomes a reality as new basic research and clinical trials show promise of efficiency for the treatment of diseases of ischemic organs. In this study we showed the effective use of modified stem cells in the recovery of blood flow in an ischemic hind-limb of type II diabetic animal models through the modulation of eNOS, HIF and VEGF/VEGF receptor pathways. These data offer a new direction in the understanding of the biological effects of administered stem cells prestimulated with EGF in the treatment of ischemic tissue diseases.
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